Aspirin May Reduce Risk of Aggressive Prostate Cancer

Aspirin May Reduce Risk of Aggressive Prostate Cancer
shutterstock_180366671A new study assessing the effect of Aspirin in decreasing prostate cancer risk will be presented at the 13th Annual American Association for Cancer Research Frontiers in Cancer Prevention Research Conference, held in New Orleans, LA. Dr. Adriana Vidal, an assistant professor of urology at Duke University in Durham, North Carolina, and colleagues have performed a clinical trial, called Reduce, sponsored by GlaxoSmithKline, to test if dutasteride reduces the risk of prostate cancer in 6,390 men without the disease. This drug, manufactured by GlaxoSmithKline, inhibits the conversion of testosterone to dihydrotestosterone, and has been used for treating benign prostatic hyperplasia (BPH), also known as “enlarged prostate.” Dr. Vidal and colleagues decided to address how the treatment with aspirin could affect the probability of men being diagnosed with prostate cancer. This hypothesis was based on previous observation that anti-inflammatory medications, such as aspirin, could decrease the levels of prostate-specific antigen (PSA), a protein that is produced by the prostate gland that upon increased levels is considered a biomarker for prostate cancer. Three groups of men were either administered aspirin, a non-steroidal anti-i
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *